RPRD2

Across TCGA pan-cancer cohorts, RPRD2 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of RPRD2’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where RPRD2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types RPRD2 is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.

COAD, LUAD, and LSCC are the cancer types where RPRD2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPRD2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Male	III,IV	+0.323	<.001	10	view →
LUAD	Male	All	+0.309	<.001	9	view →
LSCC	Male	All	+0.343	<.001	8	view →
HNSC	Male	All	+0.189	<.001	8	view →
PDAC	All	All	−0.110	.002	5	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

RPRD2–COAD

Open the COAD breakdown →